NovaBridge Biosciences Executive Begins Open-Market ADS Purchases

Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialNovaBridge Biosciences ( (NBP) ) has provided an announcement. On January 21, 2026, NovaBridge Biosciences announced that its Chief Business Development Officer and board member, Dr. Sean Cao, has begun purchasing the company’s American depositary shares in the open market, with plans to buy up to $100,000 of ADSs, although the exact number of shares and timeline for these transactions remain uncertain. The insider buying by a senior executive signals internal confidence in NovaBridge’s prospects as it advances a pipeline of drug candidates including givastomig, ragistomig, uliledlimab and VIS-101, but the company cautions that its progress remains subject to clinical, regulatory, market and financing risks outlined in its U.S. securities filings. The most recent analyst rating on (NBP) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on NovaBridge Biosciences stock, see the NBP Stock Forecast page. Spark’s Take on NBP Stock According to Spark, TipRanks’ AI Analyst, NBP is a Neutral. The score is primarily held back by deteriorated financial performance (no 2024 revenue, persistent losses, and ongoing cash burn) despite low leverage. Technicals are mildly bearish with price below key moving averages and a slightly negative MACD, while valuation is largely neutral because negative earnings make the P/E less informative and no dividend support is shown. To see Spark’s full report on NBP stock, click here. More about NovaBridge Biosciences NovaBridge Biosciences is a foreign private issuer in the biotechnology and biopharmaceutical sector, focused on developing innovative drug candidates including monoclonal antibody and immuno-oncology therapies such as givastomig, ragistomig, uliledlimab and VIS-101. The company is listed in the United States via American depositary shares (ADSs) and targets global markets for novel therapeutics, while relying on external partners for aspects of drug development, manufacturing and related services. Average Trading Volume: 749,440 Technical Sentiment Signal: Buy Current Market Cap: $451.9M For an in-depth examination of NBP stock, go to TipRanks’ Overview page.